Darapladib China PK

Summary

Darapladib China PK is a clinical trial^[1].

Key Facts

• Darapladib China PK's instance of is recorded as clinical trial^[2].
• Darapladib China PK's start time is recorded as +2013-10-23T00:00:00Z^[3].
• Darapladib China PK's end time is recorded as +2014-01-04T00:00:00Z^[4].
• Darapladib China PK's sponsor is recorded as GSK^[5].
• Darapladib China PK's main subject is recorded as atherosclerosis^[6].
• Darapladib China PK's number of participants is recorded as {'unit': '1', 'amount': '+24'}^[7].
• Darapladib China PK's title is recorded as A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.^[8].
• Darapladib China PK's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[9].
• Darapladib China PK's ClinicalTrials.gov ID is recorded as NCT02000804^[10].
• Darapladib China PK's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+45'}^[11].
• Darapladib China PK's research intervention is recorded as darapladib^[12].
• Darapladib China PK's clinical trial phase is recorded as phase I clinical trial^[13].
• Darapladib China PK's research site is recorded as GSK^[14].
• Darapladib China PK's research subject recruitment status is recorded as completed^[15].
• Darapladib China PK's study type is recorded as interventional study^[16].